ILMN vs IQV
Illumina, Inc. and IQVIA, both Healthcare
IQVIA is the larger company at $28B against $25B. On trailing earnings IQV is the cheaper of the two at a P/E of 32.5 against 42.0, a gap that is only a bargain if the two are growing at similar rates. Over the past year ILMN returned +136% against +47% for IQV. Ryufin's sector-relative Smart Score puts IQV ahead, 9/10 against 7/10.
| Figure | ILMN | IQV |
|---|---|---|
| Last close | $225 | $262 |
| Market cap | $25B | $28B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 42.0 | 32.5 |
| 1-year return | +136% | +47% |
| 5-year return | -53% | +5.6% |
| Ryufin Smart Scoresector-relative, 1–10 | 7/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Illumina, Inc.
Revenue of $1.2B in Q2 2026, net income $207M. Its largest reported line is United States And Canada, 54% of the disclosed total.
IQVIA
Revenue of $4.2B in Q1 2026, net income $274M. Its largest reported line is Research And Development Solutions, 56% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.